These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30184117)

  • 1. Cholera: Immunity and Prospects in Vaccine Development.
    Harris JB
    J Infect Dis; 2018 Oct; 218(suppl_3):S141-S146. PubMed ID: 30184117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
    Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
    mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
    Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
    Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.
    Sayeed MA; Bufano MK; Xu P; Eckhoff G; Charles RC; Alam MM; Sultana T; Rashu MR; Berger A; Gonzalez-Escobedo G; Mandlik A; Bhuiyan TR; Leung DT; LaRocque RC; Harris JB; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET
    PLoS Negl Trop Dis; 2015; 9(7):e0003881. PubMed ID: 26154421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults.
    Falkard B; Charles RC; Matias WR; Mayo-Smith LM; Jerome JG; Offord ES; Xu P; Kováč P; Ryan ET; Qadri F; Franke MF; Ivers LC; Harris JB
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007057. PubMed ID: 30703094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.
    Leung DT; Uddin T; Xu P; Aktar A; Johnson RA; Rahman MA; Alam MM; Bufano MK; Eckhoff G; Wu-Freeman Y; Yu Y; Sultana T; Khanam F; Saha A; Chowdhury F; Khan AI; Charles RC; Larocque RC; Harris JB; Calderwood SB; Kovác P; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2013 Jun; 20(6):780-8. PubMed ID: 23515016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of Protection for Cholera.
    Iyer AS; Harris JB
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S732-S737. PubMed ID: 34668561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.
    Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB
    Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttranslational Regulation of IL-23 Production Distinguishes the Innate Immune Responses to Live Toxigenic versus Heat-Inactivated Vibrio cholerae.
    Weil AA; Ellis CN; Debela MD; Bhuiyan TR; Rashu R; Bourque DL; Khan AI; Chowdhury F; LaRocque RC; Charles RC; Ryan ET; Calderwood SB; Qadri F; Harris JB
    mSphere; 2019 Aug; 4(4):. PubMed ID: 31434744
    [No Abstract]   [Full Text] [Related]  

  • 16. Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.
    Fakoya B; Sit B; Waldor MK
    J Bacteriol; 2020 Nov; 202(24):. PubMed ID: 32540930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
    Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
    PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine.
    Adekunle O; Dretler A; Kauffman RC; Cho A; Rouphael N; Wrammert J
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009743. PubMed ID: 34478460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
    Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
    Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G
    BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.